-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Medroxyprogesterone Acetate EP Impurity G
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/595-33-5.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 595-33-5 |
| Description | Medroxyprogesterone Acetate EP Impurity G is a synthetic progesteronal agent with an IC50 of 260 μM for the inhibition of HepG2. Medroxyprogesterone Acetate EP Impurity G is a manufactured hormone of the progestin type. |
Product Information
| Synonyms | Medroxyprogesterone Acetate Impurity G; 6-Methyl-3,20-dioxopregna-4,6-dien-17-yl acetate; Megestrol acetate; Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-; 17-(Acetyloxy)-6-methylpregna-4,6-diene-3,20-dione; Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-, acetate; 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; 17α-Acetoxy-6-dehydro-6-methylprogesterone; 17α-Acetoxy-6-methylpregna-4,6-diene-3,20-dione; 17α-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; 6-Dehydro-6-methyl-17α-acetoxyprogesterone; 6-Methyl-17α-acetoxy-4,6-pregnadiene-3,20-dione; 6-Methyl-17α-hydroxy-Δ6-progesterone acetate; 6-Methyl-6-dehydro-17α-acetoxyprogesterone; 6-Methyl-Δ4,6-pregnadien-17α-ol-3,20-dione acetate; BDH 1298; DMAP; Magestin; Maygace; Megace; Megalia; Megeron; Megestat; Megestil; Megestin; Megestryl acetate; MGA; Nia; Niagestin; NSC 71423; Ovaban; Ovarid; Medroxy Progesterone EP Impurity G |
| IUPAC Name | [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate |
| Molecular Weight | 384.51 |
| Molecular Formula | C24H32O4 |
| Canonical SMILES | CC1=CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C |
| InChI | InChI=1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18-,19+,20+,22-,23+,24+/m1/s1 |
| InChIKey | RQZAXGRLVPAYTJ-GQFGMJRRSA-N |
| Boiling Point | 507.1±50.0°C at 760 mmHg |
| Melting Point | 214°C |
| Flash Point | 218.5±30.2 °C |
| Purity | 98% |
| Density | 1.15±0.1 g/cm3 |
| Solubility | Soluble in Acetone, Alcohol (Sparingly), Methanol, Water (Practically) |
| Appearance | White to off-white Solid |
| Storage | RT |
| Complexity | 821 |
| Exact Mass | 384.23005950 |
| Index Of Refraction | 1.551 |
| In Vitro | Megestrol acetate alone results in an ICKY of 48.7 p,M in the MCF7/ADR cell line. |
| In Vivo | Megestrol acetate (100 or 300 mg/kg, Subcutaneously daily over a 7-day period) is able to reduce the weight loss produced by both TNF and by the MAC16 tumour. Animal Model: Pure strain female NMRI mice (age 6 to 8 weeks) Dosage: 100 or 300 mg/kg (50 mg megestrol acetate was suspended in 3 ml of pure corn oil) Administration: Subcutaneously daily over a 7-day period. |
| PSA | 60.44000 |
| Target | Progesterone Receptor; Autophagy; HIV |
| Vapor Pressure | 0.0±1.3 mmHg at 25°C |
| XLogP3-AA | 3.1 |
